Skip to main content Skip to navigation
Hamburger Menu
Search icon
Country Selector Country Selector
Finland (English)
Profile Icon Profile Icon
Sign-in/Register UserName
Products

Solutions

Discover & Learn

Resources & Tools

Support

Search icon Search icon
Close Menu
      Alert Icon
      Anti-Terminal-Deoxynucleotidyl Transferase (TdT) FITC
      Product Details
      Down Arrow Up Arrow


      BD™
      TdT; DNTT; Terminal transferase; Terminal addition enzyme
      Human
      Mouse BALB/c IgG1, κ
      Purified Human TdT
      Intracellular staining (flow cytometry)
      12.5 μg/mL
      20 μL
      1791
      Phosphate buffered saline with gelatin and 0.1% sodium azide.
      CE_IVD


      Preparation And Storage

      The antibody reagent is stable until the expiration date shown on the label when stored at 2° to 8°C. Do not use after the expiration date. Do not freeze the reagent or expose it to direct light during storage or incubation with cells. Keep the outside of the reagent vial dry.

      Do not use the reagent if you observe any change in appearance. Precipitation or discoloration indicates instability or deterioration.

      Show More blue down arrow Show Less blue up arrow
      332789 Rev. 1
      Antibody Details
      Down Arrow Up Arrow
      E17-1519

      Anti–terminal-deoxynucleotidyl transferase (TdT) is intended for in vitro diagnostic use in the identification of cells expressing this enzymatic marker, using a BD FACS™ brand flow cytometer.

      The flow cytometer must be equipped to detect light scatter and the appropriate fluorescence, and be equipped with appropriate analysis software (such as BD CellQuest™ or BD LYSYS™ II software) for data acquisition and analysis. Refer to your instrument user’s guide for instructions.

      332789 Rev. 1
      Format Details
      Down Arrow Up Arrow
      FITC
      Fluorescein (FITC) is part of the BD blue family of dyes. This is a small organic fluorochrome with an excitation maximum (Ex Max) at 494-nm and an emission maximum (Em Max) at 518-nm. FITC is designed to be excited by the Blue laser (488-nm) and detected using an optical filter centered near 520 nm (e.g., a 530/30-nm bandpass filter). Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
      altImg
      FITC
      Blue 488 nm
      494 nm
      518 nm
      332789 Rev.1
      Citations & References
      Down Arrow Up Arrow

      Development References (28)

      1. Alt FW, Baltimore D. Joining of immunoglobulin heavy chain gene segments: implications from a chromosome with evidence of three D-JH fusions. Proc Natl Acad Sci USA. 1982; 79:4118-4122. (Biology).
      2. Alt FW, Oltz EM, Young F, Gorman J, Taccioli G, Chen J. VDJ recombination. Immunol Today. 1992; 13(8):306-314. (Biology).
      3. Baltimore D. Is terminal deoxynucleotidyl transferase a somatic mutagen in lymphocytes?. Nature. 1974; 409-411. (Biology).
      4. Bearman RM, Winberg CD, Maslow WC, et al. Terminal deoxynucleotidyl transferase activity in neoplastic and non-neoplastic hematopoietic cells. Am J Clin Pathol. 1981; 75:794-802. (Biology).
      5. Bollum FJ. Terminal deoxynucleotidyl transferase as a hematopoietic cell marker. Blood. 1979; 54:1203-1215. (Biology).
      6. Bonati A, Zanelli P, Ferrari S, et al. T-cell receptor β-chain gene rearrangement and expression during human thymic ontogenesis. Blood. 1992; 79:1472-1483. (Biology).
      7. Centers for Disease Control. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in healthcare settings. MMWR. 1988; 37:377-388. (Biology).
      8. Clevers H, Alarcón B, Wileman T, Terhorst C. The T cell receptor/CD3 complex: a dynamic protein ensemble. Annual Rev Immunol. 1988; 6:629. (Biology).
      9. Clinical Applications of Flow Cytometry: Quality Assurance and Immunophenotyping of Lymphocytes: Approved Guideline. NCCLS document H42-A. 1998. (Biology).
      10. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Rothe G, Schmitz G. Leukemia. 1996; 10:877-895. (Biology).
      11. Desiderio SV, Yancopoulos GD, Paskind M, et al. Insertion of N regions into heavy-chain genes is correslated with expression of terminal deoxytransferase in B cells. Nature. 1984; 311:752-755. (Biology).
      12. Fuller SA, Phillips A, Coleman MS. Affinity purification and refined structural characterization of terminal deoxyribonucleotidyl transferase. Biochem J. 1985; 231:105-113. (Biology).
      13. Gore SD, Kastan MB, Civin CI. Normal human bone marrow precursors that express terminal deoxynucleotidyl transferase include T-cell precursors and possible lymphoid stem cells.. Blood. 1991; 77(8):1681-90. (Biology). View Reference
      14. Horvatinovich JM, Sparks SD, Borowitz MJ. Detection of terminal deoxynucleotidyl transferase by flow cytometry: a three color method. Cytometry. 1994; 18:228-230. (Biology).
      15. Jackson AL, Warner NL. Rose NR, Friedman H, Fahey JL, ed. Manual of Clincial Laboratory Immunology, Third Edition. Washington DC: American Society for Microbiology; 1986:226-235.
      16. Komori T, Okada A, Stewart V, Alt FW. Lack of N regions in antigen receptor variable regions of TdTdeficient lymphocytes. Science. 1993; 261:1171-1175. (Biology).
      17. Kung PC, Long JC, McCaffrey RP, Ratliff RL, Harrison TA, Baltimore D. Terminal deoxynucleotidyl transferase in the diagnosis of leukemia and malignant lymphoma. Am J Med. 1978; 64(5):788-794. (Biology).
      18. Landau NR, Schatz DG, Rosa M, Baltimore D. Increased frequency of N-region insertion in a murine pre–B-cell line infected with a terminal deoxynucleotidyl transferase retroviral expression vector. Mol Cell Biol. 1987; 7:3237-3243. (Biology).
      19. McCaffrey R, Harrison TA, Parkman R, Baltimore D. Terminal deoxynucleotidyl transferase activity in human leukemic cells and in normal human thymocytes. N Engl J Med. 1975; 292(15):775-780. (Biology).
      20. McCaffrey R, Smoler DF, Baltimore D. Terminal deoxynuicleotidyl transferase in a case of childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 1973; 70:521-525. (Biology).
      21. Muehleck SD, McKenna RW, Gale PF, Brunning RD. Terminal deoxynucleotidyl transferase (TdT)-positive cells in bone marrow in the absence of hematologic malignancy. Am J Clin Pathol. 1983; 79:277-284. (Biology).
      22. Murphy S, Jaffe ES. Terminal transferase activity and lymphoblastic neoplasms. N Engl J Med. 1984; 311:1373-1375. (Biology).
      23. NCCLS document. 2001. (Biology).
      24. Paietta E, Meenan B, Heavey C, Thomas D. Detection of terminal transferase in acute myeloid leukemia by flow cytometry. Cytometry. 1994; 16:256-261. (Biology).
      25. Roma AO, Kutok JL, Shaheen G, Dorfman DM. A novel, rapid, multiparametric approach for flow cytometric analysis of intranuclear terminal deoxynucleotidyl transferase. Am J Clin Pathol. 1999; 112:343-348. (Biology).
      26. Stelzer GT, Marti G, Hurley A, McCoy PJ, Lovett EJ, Schwartz A. US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry. 1997; 30:214-230. (Biology).
      27. Waldmann TA. The arrangement of immunoglobulin and T cell receptor genes in human lymphoproliferative disorders. Adv Immunol. 1987; 40:247-321. (Biology).
      28. Weiss LM, Bindl JM, Picozzi VJ, Link MP, Warnke RA. Lymphoblastic lymphoma: an immunophenotype study of 26 cases with comparison to T cell acute lymphoblastic leukemia. Blood. 1986; 67(2):474-478. (Biology).
      View All (28) View Less
      332789 Rev. 1

      Please refer to Support Documents for Quality Certificates


      Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


      Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

      For In Vitro Diagnostic Use.

       

      23-22942-00

      Documents are subject to revision without notice. Please verify you have the correct revision of the document, and always refer back to BD's eIFU website for the latest and most up to date information.

      Website Feedback